|
Goldline Pharmaceutical Ltd
|
|
info@goldlinepharma.in Website:www.goldlinepharma.in
|
|
Initial public offer of upto 27,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Goldline Pharmaceutical Limited ("Issuer" or "The" "company") at an issue price of Rs.41-43 per equity share (including a share premium of Rs.31-33 per equity share) for cash, aggregating up to Rs.11.07-11.61 Crores ("Public Issue") out of which 1,38,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 41-43 per equity share for cash, aggregating Rs. 0.57-0.59 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 25,62,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 41-43 per equity share for cash, aggregating up to Rs. 10.50-11.02 Crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 28.13% and 26.69% respectively of the post-issue paid-up equity share capital of the company.
Price Band is Rs. 41 to Rs. 43 per equity share of face value of Rs. 10/- each.
The floor price is 4.1 times of the face value and the cap price is 4.3 times of the face value.
Bids can be made for a minimum of Two lot and in multiples of 3,000 equity shares thereafter.
|
|
|
|
|
|
|
Goldline Pharmaceutical Ltd
|
| |
Rs Cr |
Lead Managers to the Issue |
| 0.00 |
| Cumulative Capital Private Limited |
|
| 11.07 |
|
| 9.60 |
|
| Rs.
41.00
|
|
|
|
|
|
| Projects |
|
Repayment of all or a portion of certain outstanding borrowings availed by its company
|
General Corporate Purpose
|
|
|
| Amol Laxmikant Mujumdar |
| Swapan Premprakash Khandelwal |
| Asha Swapan Khandelwal |
|
|
|
| |
|
|